Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

October 25th 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

FDA Grants Fast Track Designation to HC-7366 in Relapsed/Refractory AML

October 25th 2024

HC-7366 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis

October 25th 2024

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma

October 23rd 2024

Binod Dhakal, MD, MS, discusses updated survival data from the CARTITUDE-4 trial of cilta-cel in pretreated, lenalidomide-refractory multiple myeloma.

Dr Ducreux on the Potential Use of Liver Transplantation Plus Chemo for CRC Liver Metastases

October 23rd 2024

Michel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

October 17th 2024

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

October 17th 2024

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

October 17th 2024

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

October 16th 2024

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis

October 16th 2024

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

October 16th 2024

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

VCN-01 Earns Orphan Medicinal Product Designation in Europe for Retinoblastoma

October 16th 2024

The European Commission has granted orphan medicinal product designation to VCN-01 for the treatment of patients with retinoblastoma.

ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer

October 15th 2024

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

October 14th 2024

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

EU Approval Sought for Darolutamide Plus ADT for mHSPC

October 14th 2024

The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

October 14th 2024

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL

October 11th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

October 11th 2024

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.